{"url_path":"/sec/vrdn/8-k/2026-06-29/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-286273-index.html","accession_number":"0001193125-26-286273","cik":"0001590750","ticker":"VRDN","issuer_name":"Viridian Therapeutics, Inc.\\DE","edgar_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-286273-index.html","primary_entity_key":"0001590750","primary_entity_name":"Viridian Therapeutics, Inc.\\DE"},"word_count":156,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure\n\nOn June 26, 2026, Viridian Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (“TED”) regardless of activity or duration. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information in this Item 7.01 and in Exhibit 99.1 to this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing."}